Clinical Trial Update: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tumor-infiltrating lymphocytes (TIL) immunotherapy for metastatic ocular/uveal melanoma; study terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Melanoma
• Uveal Melanoma

Drugs mentioned

• Tumor Infiltrating Lymphocytes (TIL) Immunotherapy (tumor-infiltrating lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-07-24